多西他赛联合奈达铂治疗复发转移性鼻咽癌的临床研究.pdfVIP

实用临床医药杂志 2012 年第 16 卷第3 期 Joumal of Clinical Medicine in Practice • 87 • 多西他赛联合奈达铅治疗复发转移性 鼻咽癌的临床研究 黄汉生，杨兰平 (广西壮族自治区柳州市肿瘤医院化疗科，广西柳州， 545ω的 摘要:目的探讨多西他赛联合奈达锦治疗复发和(或)转移性单啊瘤的l临床疗效及不良反应。方法复发和(或)转移 性鼻啊癌患者40 例，经2 个周期以上多西他赛联合奈达锦化疗后，评价临床疗效J远不良反应。结果 40 例患者均按化疗方案 完成化疗，每例患者完成化疗 2-4 个周期，共完成 134 个周期化疗。化疗结束时有效率为85.0% ，化疗后3 个月 RR 为 92. 5%。中位无疾病进展时间 7.9 个月; 1 年生存率92.5%. 中位生存时间 18.7 个月。不良反应主要以骨髓抑制为主。结论 多因他赛联合奈达锦治疗复发和{或)转移性鼻咽癌有效率高，为有效治疗方案。 关键词:多西他赛z 奈达铺z 复发转移性鼻咽癌 中图分类号: R 730.53; R 739.63 文献标志码:A 文章编号: 1672 - 2353(2012 )03 - 0087 - 03 Docetaxel combined with nedapIatin in the treatment of recurrent metastatic nasopharyngeal carcinoma IllJANG Han - sheng , YANG Lan - ping (Liu动ou (Àncer F如户ital ， Líu劝棚，Gz皿ngxi ， 545ω6) A即fRACf: Obj民tive To explore the clinical efficacy and adverse reactions of docetaxel ∞mbined with nedaplatin for r，四JITent metastatic nasopharyngeal 臼rcinαna. Methods Forty pa- tients with recurrent metastatic nasopharyngeal 也rcinoma were included in the study.τbe clinical efficacy and adverse reactions we陀 evaluated after they received two 一叮de chemotherapy of doc- etaxel combined with nedaplatin. R臼ults All patients ∞mpleted chemotherapy. Each patient com- pleted 2ω4 cycl臼. A total of 134 cyd臼of chemotherapy were re∞，rded. At the end of chemother- apy , the effìcacy rate w.臼 85.0% ， and it w部92.5% thr回months later. The median time of pro- grl臼sion w.臼 7.9 months. 1 - y四r survival rate w;部92.5% ， and the median survival time w臼 18. 7 months. The main adverse events were bone marrow suppressions. Concl皿ion 如cetaxel com- bined with nedaplatin for recurr四t metastatic nasopharyngeal 四rcinorna is effective. KE